Advertisement

Tumor Specific Conversion of a Pyrimidine Antimetabolite

  • H. R. Hartmann
  • W. Bollag
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 165)

Abstract

5-Fluorouracil (5-FU) was the first of a series of pyrimidine antimetabolites possessing a growth inhibitory effect on transplantable tumors. Its usefulness in clinical cancer chemotherapy is established. Considerable efforts have been made towards finding 5-FU derivatives with better antitumor activity and less toxicity. 5′-dFUR, a novel pyrimidine analog, has been shown to possess both a high cytostatic activity against a broad spectrum of experimental tumors and a low toxicity. In vitro, however, medium concentrations needed for 50% growth inhibition are much higher for 5′-dFUR than for 5-FU or 2′-deoxy-5-fluorouridine (FUdR) and vary markedly from cell line to cell line.

Keywords

Lewis Lung Carcinoma Transplantable Tumor Pyrimidine Nucleoside Pyrimidine Analog Average Tumor Weight 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • H. R. Hartmann
    • 1
  • W. Bollag
    • 1
  1. 1.Pharmaceutical Research DepartmentF.Hoffmann-La Roche & Co. Ltd.BaselSwitzerland

Personalised recommendations